Actavis to buy Forest for $25 billion
21-02-2014
Forest Laboratories, a subsidiary of Allergan, has failed in its attempt to overturn a district court ruling in its patent battle with Teva.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Forest Laboratories, Teva, patent, Alzheimer’s, Allergan, Namenda XR
